STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLX
  4. [Form 4] CLOROX CO /DE/ Insider Trading Activity

Clorox (CLX) director logs deferred stock units from awards and fees

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.

On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.

Positive

  • None.

Negative

  • None.
Insider Breber Pierre R
Role Director
Type Security Shares Price Value
Grant/Award Deferred Stock Units 1,637.858 $0.00 --
Grant/Award Deferred Stock Units 334.722 $0.00 --
Grant/Award Deferred Stock Units 8.935 $0.00 --
Holdings After Transaction: Deferred Stock Units — 2,412.618 shares (Direct)
Footnotes (1)
  1. 1-for-1 Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director. Annual award of Deferred Stock Units pursuant to the 2005 Stock Incentive Plan. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Breber Pierre R
(Last) (First) (Middle)
1221 BROADWAY
(Street)
OAKLAND CA 94612-1888
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Stock Units (1) 11/06/2025 A(2) V 8.9351 (3) (3) Common Stock 8.9351 $0.0000 774.7598 D
Deferred Stock Units (1) 12/31/2025 A(4) 1,637.8577 (3) (3) Common Stock 1,637.8577 $0.0000 2,412.6175 D
Deferred Stock Units (1) 12/31/2025 A(5) 334.7218 (3) (3) Common Stock 334.7218 $0.0000 2,747.3393 D
Explanation of Responses:
1. 1-for-1
2. Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.
3. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.
4. Annual award of Deferred Stock Units pursuant to the 2005 Stock Incentive Plan.
5. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.
By Jinho Joo, Attorney-in-Fact 01/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Clorox (CLX) report in this Form 4?

The filing reports that a Clorox Co. director acquired deferred stock units linked to Clorox common stock as part of director compensation and fee deferrals.

How many deferred stock units did the Clorox director receive on 11/06/2025?

On 11/06/2025, the director acquired 8.9351 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan.

What equity awards did the Clorox (CLX) director receive on 12/31/2025?

On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, plus 334.7218 deferred stock units in lieu of quarterly director fees.

What is the director’s total deferred stock unit holding after these transactions?

Following the reported transactions, the director beneficially owns 2,747.3393 deferred stock units tied to Clorox common stock.

How and when will the Clorox director’s deferred stock units be settled?

The deferred stock units will be settled 100% in Clorox stock when the director retires or otherwise terminates service from the board.

Why did the Clorox director receive some deferred stock units instead of cash fees?

A portion of the units, totaling 334.7218 deferred stock units, represents the receipt of deferred stock units in lieu of quarterly director fees.